Skip to content

Effects of Meditation on Mechanism of Coronary Heart Disease

Effects of Meditation on Mechanism of Coronary Heart Disease

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00010738
Enrollment
145
Registered
2001-02-05
Start date
1999-09-30
Completion date
2002-08-31
Last updated
2006-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Brief summary

To study the effects of Transcendental Meditation on Coronary Heart Disease

Detailed description

Recent advances in our understanding of the pathophysiology of acute cardiac events - specifically, identification of the roles that arterial vasomotor dysfunction and autonomic nervous system imbalances play in the pathophysiologic cascade during such acute events - provides a platform for new mechanistic investigation of the interplay of psychosomatic stress and CHD (coronary heart disease). Preliminary evidence further suggests that Complementary and Alternative Medicine (CAM) practices, such as the Transcendental Meditation (TM) technique, can not only reduce stress but also reduce acute cardiac events in patients with CHD. Based on these and related data, we propose a randomized, blinded, controlled study of the effects of one CAM practice, the TM technique, compared to a control group, on the primary outcomes of (1) arterial vasomotor dysfunction (brachial artery reactivity); (2) autonomic nervous system imbalances (heart rate variability); (3) transient myocardial ischemia (ST-segment depression); and (4) the secondary outcomes of psychological stress and quality of life (anger, hostility, anxiety, depression, perceived health, disease-specific symptoms, and life stress/social resources).

Interventions

PROCEDUREMeditation

Sponsors

National Center for Complementary and Integrative Health (NCCIH)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Able to attend training sessions and meetings * Local residence

Exclusion criteria

* Comorbid disease precluding survival in group * MI, unstable angina, CABG or PTCA within last three months. * Cognitive/psychological/substance abuse impairment * Atrial fibrillation, predominant pacemaker rhythm or significant conduction system disease * Significant valvular heart disease * Class III or IV heart failure * Renal failure * Participating in a formal stress management program * Participation in another trial

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026